Plasmodium falciparum malaria
ICD-10 B51.0 is a billable code used to indicate a diagnosis of plasmodium falciparum malaria.
Plasmodium falciparum malaria is a severe form of malaria caused by the Plasmodium falciparum parasite, which is transmitted to humans through the bite of infected Anopheles mosquitoes. This species is responsible for the majority of malaria-related morbidity and mortality worldwide, particularly in sub-Saharan Africa. Clinical manifestations can range from mild flu-like symptoms to severe complications such as cerebral malaria, acute respiratory distress syndrome, and multi-organ failure. Diagnosis is typically confirmed through blood smears or rapid diagnostic tests that detect specific antigens. Treatment involves the use of antimalarial medications, with artemisinin-based combination therapies (ACTs) being the first-line treatment. However, resistance to antimalarial drugs, particularly artemisinin, has been reported in some regions, complicating treatment strategies. Prophylaxis is recommended for travelers to endemic areas, utilizing medications such as atovaquone-proguanil or mefloquine, along with preventive measures like insect repellent and bed nets.
Detailed travel history, laboratory results, and treatment plans.
Patients presenting with fever and travel history to endemic areas.
Need for accurate species identification and awareness of local resistance patterns.
Prophylaxis prescriptions, patient education on prevention.
Pre-travel consultations for individuals traveling to malaria-endemic regions.
Emphasis on preventive measures and understanding of local malaria transmission dynamics.
Used when testing for malaria in symptomatic patients.
Document the reason for testing and results.
Infectious disease specialists should ensure accurate interpretation of results.
The primary treatment for Plasmodium falciparum malaria is artemisinin-based combination therapy (ACT), which is effective against this species and helps reduce the risk of resistance.
